Bioverge

Bioverge

Testing the Waters

Bioverge is an investment platform that funds visionary entrepreneurs with the aim of transforming healthcare and bringing science fiction to life.

Bioverge is an investment platform that funds visionary entrepreneurs with the aim of transforming healthcare and bringing science fiction to life.

Overview

Raised to Date: Raised: $0

Total Commitments ($USD)

Platform

Netcapital

Start Date

04/27/2021

Close Date

Testing the Waters

Min. Goal
Funded
Max. Goal
Funded
Min. Investment

$99

Security Type

Equity - Common

SEC Filing Type

Test the Waters / RegCF    Open SEC Filing

Price Per Share

$1.14

Pre-Money Valuation

$10,014,900

Rolling Commitments ($USD)

Status
Funded
Reporting Date

05/30/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$0

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2017

Industry

Financial & Insurance Products & Services

Tech Sector

Fintech

Location

San Francisco, California

Bioverge, with a post-money valuation of $11 million, is testing the waters on NetCapital. It is an investment platform that funds entrepreneurs with the aim to transform healthcare. The platform allows both accredited and non-accredited investors to invest in healthcare startups and support them. Neil J. Littman and Rick Gibb founded Bioverge in 2017. The current crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,069,999, and the funds will be used for product development, sales and marketing, and general and administrative expenses. Bioverge has successfully closed 32 deals across 21 portfolio companies.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Bioverge 08/06/2023 Republic $25,000,000 $138,007 SAFE Funded RegCF
Bioverge 02/27/2022 Netcapital $10,014,900 $710,266 Equity - Common Funded RegCF
Bioverge 05/12/2021 Netcapital $10,014,900 $0 Equity - Common Funded Test the Waters / RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Bioverge on NetCapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $10,014,900
Price per Share: $1.14

Follow company

Follow Bioverge on NetCapital

Buy Bioverge's Deal Report

Warning: according to the close date for this deal, Bioverge may no longer be accepting investments.

Bioverge Deal Report

Get KingsCrowd’s comprehensive report on Bioverge including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Bioverge is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Bioverge deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge